Scarica l'app Stockscreener
7.15
4.92%
-0.37
Dopo l'orario di chiusura:
7.40
0.25
+3.50%
Precedente Chiudi:
$7.52
Aprire:
$7.5308
Volume 24 ore:
14,123
Relative Volume:
0.48
Capitalizzazione di mercato:
$11.76M
Reddito:
$1.47M
Utile/perdita netta:
$-97.61M
Rapporto P/E:
-4.7987
EPS:
-1.49
Flusso di cassa netto:
$-80.90M
1 W Prestazione:
-10.29%
1M Prestazione:
+11.37%
6M Prestazione:
+55.43%
1 anno Prestazione:
-40.47%
Intervallo 1D:
$7.10
$7.5575
Intervallo di 1 settimana:
$7.00
$8.0499
Portata 52W:
$3.8101
$37.50
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Nome
Lyra Therapeutics Inc
Settore
Industria
Telefono
617-373-4600
Indirizzo
480 ARSENAL WAY, WATERTOWN, MA
Confronta LYRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
7.15 | 12.12M | 1.47M | -97.61M | -80.90M | -1.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-07 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-05-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-05-07 | Downgrade | Jefferies | Buy → Hold |
| 2024-05-06 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-06 | Ripresa | BTIG Research | Buy |
| 2023-08-31 | Iniziato | H.C. Wainwright | Buy |
| 2022-05-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-05-26 | Iniziato | BTIG Research | Buy |
| 2020-05-26 | Iniziato | BofA/Merrill | Buy |
| 2020-05-26 | Iniziato | Jefferies | Buy |
| 2020-05-26 | Iniziato | William Blair | Outperform |
Mostra tutto
Lyra Therapeutics Inc Borsa (LYRA) Ultime notizie
Short interest data insights for Lyra Therapeutics Inc.2025 Price Momentum & Expert Approved Trade Ideas - newser.com
What valuation multiples suggest for Lyra Therapeutics Inc. stock2025 Key Highlights & Risk Controlled Stock Alerts - newser.com
Using data models to predict Lyra Therapeutics Inc. stock movementTreasury Yields & Daily Oversold Stock Bounce Ideas - newser.com
Regression analysis insights on Lyra Therapeutics Inc. performanceWeekly Market Report & Safe Capital Growth Tips - newser.com
Published on: 2025-10-09 05:19:19 - newser.com
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study - Sahm
Lyra Therapeutics To Conduct One More Trial For Chronic Rhinosinusitis Treatment Candidate - Stocktwits
Lyra Therapeutics Announces Clinical Plan for LYR-210 and - GlobeNewswire
Lyra Therapeutics outlines path to NDA for CRS treatment - Investing.com
Lyra Therapeutics (LYRA) Advances CRS Treatment with Positive Tr - GuruFocus
Lyra Therapeutics outlines path to NDA for CRS treatment By Investing.com - Investing.com Australia
Lyra unveils clinical plan for LYR-210, to present late-stage sinusitis trial data - MarketScreener
Lyra Therapeutics Announces Clinical Plan for LYR-210 Following Positive ENLIGHTEN 2 Results and Upcoming FDA Engagement - Quiver Quantitative
Lyra Therapeutics, Inc. Announces Clinical Plan for Lyr-210 and Late-Breaking Oral Presentation of Phase 3 Enlighten 2 Study - MarketScreener
Multi asset correlation models including Lyra Therapeutics Inc.Weekly Profit Analysis & AI Powered Market Entry Strategies - newser.com
24-Week Phase 3 Win: Lyra's LYR-210 Shows CRS Improvement; FDA Requires Additional Trial - Stock Titan
What the charts say about Lyra Therapeutics Inc. todayJuly 2025 Selloffs & Intraday High Probability Setup Alerts - newser.com
Using Python tools to backtest Lyra Therapeutics Inc. strategiesMarket Volume Summary & Real-Time Volume Triggers - newser.com
Is Lyra Therapeutics Inc. stock supported by strong cash flowsLayoff News & Free Weekly Chart Analysis and Trade Guides - newser.com
What analysts say about Lyra Therapeutics Inc stockRisk Adjusted Returns & Free Stock Price Trend Analysis - earlytimes.in
Is Lyra Therapeutics Inc. stock ready for a breakoutPrice Action & Growth Focused Investment Plans - newser.com
Goldman Sachs Group Inc. Sells 185,314 Shares of Lyra Therapeutics, Inc. $LYRA - Defense World
Lyra Therapeutics (NASDAQ:LYRA) Stock Price Up 0.5% – Here’s Why - Defense World
Is Lyra Therapeutics Inc a good long term investmentUtilities Sector Analysis & Target Triple-Digit Stock Opportunities - earlytimes.in
What drives Lyra Therapeutics Inc stock priceEarnings Miss Alerts & Capital Allocation Recommendations - earlytimes.in
US Market Recap: How much upside does Lyra Therapeutics Inc haveGDP Growth & Trade Opportunity Analysis - خودرو بانک
Tech Rally: Is Lyra Therapeutics Inc stock a good pick for beginnersMarket Performance Report & Verified Technical Signals - khodrobank.com
Quantitative breakdown of Lyra Therapeutics Inc. recent moveJuly 2025 Closing Moves & High Accuracy Swing Entry Alerts - newser.com
Market Moves: Should I hold or sell Lyra Therapeutics Inc nowEarnings Summary Report & Low Risk High Reward Trade Ideas - خودرو بانک
Live market analysis of Lyra Therapeutics Inc.July 2025 Earnings & Risk Adjusted Buy and Sell Alerts - newser.com
Top chart patterns to watch in Lyra Therapeutics Inc.IPO Watch & Safe Capital Growth Trade Ideas - newser.com
Can swing trading help recover from Lyra Therapeutics Inc. lossesBull Run & Technical Entry and Exit Alerts - newser.com
Is Lyra Therapeutics Inc. a candidate for recovery playJuly 2025 Trends & Weekly Setup with ROI Potential - newser.com
Lyra Therapeutics Inc Azioni (LYRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lyra Therapeutics Inc Azioni (LYRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Palasis Maria | President & CEO |
Jul 10 '25 |
Sale |
8.91 |
1,565 |
13,944 |
1,098,435 |
| Cavalier Jason | Chief Financial Officer |
Jul 10 '25 |
Sale |
8.91 |
684 |
6,094 |
519,316 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):